ATE448214T1 - Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden - Google Patents

Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden

Info

Publication number
ATE448214T1
ATE448214T1 AT06703590T AT06703590T ATE448214T1 AT E448214 T1 ATE448214 T1 AT E448214T1 AT 06703590 T AT06703590 T AT 06703590T AT 06703590 T AT06703590 T AT 06703590T AT E448214 T1 ATE448214 T1 AT E448214T1
Authority
AT
Austria
Prior art keywords
alkyl
ppar
aryl
formula
new
Prior art date
Application number
AT06703590T
Other languages
English (en)
Inventor
Zbigniew Majka
Katarzyna Rusin
Dominik Kludkiewicz
Daniel Sulikowski
Krzysztof Kurowski
Katarzyna Matusiewicz
Tomasz Stawinski
Piotr Kowalczyk
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Application granted granted Critical
Publication of ATE448214T1 publication Critical patent/ATE448214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06703590T 2005-01-19 2006-01-17 Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden ATE448214T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL372332A PL372332A1 (pl) 2005-01-19 2005-01-19 Nowe związki, pochodne kwasu 3-fenylopropionowego
PCT/EP2006/050234 WO2006077206A1 (en) 2005-01-19 2006-01-17 New 3-phenylpropionic acid derivatives and their use as ppar- gamma rezeptor liganden

Publications (1)

Publication Number Publication Date
ATE448214T1 true ATE448214T1 (de) 2009-11-15

Family

ID=36046977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06703590T ATE448214T1 (de) 2005-01-19 2006-01-17 Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden

Country Status (25)

Country Link
US (2) US7309791B2 (de)
EP (1) EP1874745B1 (de)
JP (1) JP2008527021A (de)
KR (1) KR100889447B1 (de)
CN (1) CN101098862A (de)
AT (1) ATE448214T1 (de)
AU (1) AU2006207492B8 (de)
BR (1) BRPI0606501A2 (de)
CA (1) CA2590575C (de)
CY (1) CY1109678T1 (de)
DE (1) DE602006010353D1 (de)
DK (1) DK1874745T3 (de)
ES (1) ES2336358T3 (de)
HR (1) HRP20090647T1 (de)
IL (1) IL183564A0 (de)
MX (1) MX2007008114A (de)
NO (1) NO20074173L (de)
PL (2) PL372332A1 (de)
PT (1) PT1874745E (de)
RS (1) RS51215B (de)
RU (1) RU2369602C2 (de)
SI (1) SI1874745T1 (de)
UA (1) UA89940C2 (de)
WO (1) WO2006077206A1 (de)
ZA (1) ZA200705889B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
AU2006311523A1 (en) * 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole PPAR modulator
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
JP5357894B2 (ja) * 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
WO2016003917A1 (en) * 2014-07-03 2016-01-07 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552125A (en) 1975-06-07 1979-09-05 Lilly Industries Ltd 2-acylamino oxazoles
JPS58125039A (ja) 1982-01-21 1983-07-25 Konishiroku Photo Ind Co Ltd 写真用２当量イエロ−カプラ−
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1995025107A1 (en) 1994-03-12 1995-09-21 Yuhan Corporation Triazole compounds and processes for the preparation thereof
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PL339660A1 (en) * 1997-10-02 2001-01-02 Sankyo Co Derivatives of amidocarboxylic acids
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
EP1210345B1 (de) 1999-09-08 2004-03-03 Glaxo Group Limited Oxazol ppar antagonisten
FR2808798A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
EP1414806A1 (de) 2001-07-30 2004-05-06 Novo Nordisk A/S Neue vinyl-n-(2-benzoylphenyl)-l-tyrosinderivate und deren verwendung als antidiabetika usw.
WO2003011814A1 (en) 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego

Also Published As

Publication number Publication date
AU2006207492B8 (en) 2009-03-26
ES2336358T3 (es) 2010-04-12
US7629370B2 (en) 2009-12-08
RS51215B (sr) 2010-12-31
RU2007131423A (ru) 2009-02-27
BRPI0606501A2 (pt) 2009-06-30
EP1874745A1 (de) 2008-01-09
AU2006207492A1 (en) 2006-07-27
ZA200705889B (en) 2009-03-25
CN101098862A (zh) 2008-01-02
CY1109678T1 (el) 2014-08-13
AU2006207492B2 (en) 2009-03-05
CA2590575A1 (en) 2006-07-27
NO20074173L (no) 2007-08-14
WO2006077206A1 (en) 2006-07-27
UA89940C2 (en) 2010-03-10
JP2008527021A (ja) 2008-07-24
DE602006010353D1 (de) 2009-12-24
MX2007008114A (es) 2007-08-02
US20070161799A1 (en) 2007-07-12
PL372332A1 (pl) 2006-07-24
KR100889447B1 (ko) 2009-03-24
CA2590575C (en) 2010-09-21
US20060160868A1 (en) 2006-07-20
IL183564A0 (en) 2007-09-20
KR20070097112A (ko) 2007-10-02
PT1874745E (pt) 2010-01-13
EP1874745B1 (de) 2009-11-11
DK1874745T3 (da) 2009-12-21
HRP20090647T1 (hr) 2010-01-31
RU2369602C2 (ru) 2009-10-10
PL1874745T3 (pl) 2010-03-31
US7309791B2 (en) 2007-12-18
SI1874745T1 (sl) 2010-02-26

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
ZA200705889B (en) New 3-phenylpropionic acid derivatives and their use as PPAR-GAMMA receptor ligands
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
MX2010005717A (es) Derivados de isoxazolo-piridina.
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
CY1112800T1 (el) Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
MX9101768A (es) Derivados de tienoimidazol y metodo para su produccion
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
MX2025002452A (es) Serie de compuestos heterociclicos puenteados que contienen nitrogeno y metodo de preparacion de los mismos
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser
ZA200704584B (en) New 3-Phenylpropionic acid derivatives for the treatment of diabetes
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1874745

Country of ref document: EP